VYGR Voyager Therapeutics Inc

$VYGR not a lot of attention on this one but I'm hoping for an exit around 2.70...AS OF RIGHT NOW. $APLD $ORBS

$VYGR CTAD 2026 Alzheimer’s pipeline update. ICYMI: Voyager just dropped their PR detailing two upcoming poster presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference... and the market, IMO, is still sleeping on this setup down in the $1.70S after throwing VYGR out with the bathwater during the recent sector-wide biotech capitulation. The clinical anchors being featured: • "First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer's disease (# P055)" • "Baseline characteristics of participants enrolled in a multiple ascending dose study of the C-terminal targeting anti-tau antibody VY7523 in early Alzheimer's disease (# P054)" I'm long the common equity and have been actively writing puts to farm premium while the thesis plays out. Between the systemic BBB-penetrant capabilities, these progression updates, and the ongoing optionality of their TRACER AAV capsid discovery platform, the asymmetric risk/reward here, IMO, remains fully intact.

$VYGR unusual volume after hours, don't know this ticker well to know this after hour movement.

$VYGR hello I have not been able to figure out the triggers that are driving this thing down if one of you who’s very close to it could advise. I’d appreciate it thanks.

$VYGR First buy signal since September 2nd. Hope good news flow out of PET imaging data.

$VYGR The market is saying the anti-tau antibody would not be effective to slow down Alzeimer' progress. and they will discontinue as it cannot beat UCB's.